Marie Hairing Enemark, Jonas Klejs Hemmingsen, Maja Dam Andersen, Trine Engelbrecht Hybel, Mads Emil Bjørn, Pär Lars Josefsson, Lars Møller Pedersen, Maja Bech Juul, Robert Schou Pedersen, Michael Thorsgaard, Ida Blok Sillesen, Trine Lindhardt Plesner, Stephen Jacques Hamilton-Dutoit, Paw Jensen, Charlotte Madsen, Maja Ludvigsen
{"title":"Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort","authors":"Marie Hairing Enemark, Jonas Klejs Hemmingsen, Maja Dam Andersen, Trine Engelbrecht Hybel, Mads Emil Bjørn, Pär Lars Josefsson, Lars Møller Pedersen, Maja Bech Juul, Robert Schou Pedersen, Michael Thorsgaard, Ida Blok Sillesen, Trine Lindhardt Plesner, Stephen Jacques Hamilton-Dutoit, Paw Jensen, Charlotte Madsen, Maja Ludvigsen","doi":"10.1038/s41408-024-01150-3","DOIUrl":"https://doi.org/10.1038/s41408-024-01150-3","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"8 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142330316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ece Özoğul, Anna Montaner, Melina Pol, Gerard Frigola, Olga Balagué, Charlotte Syrykh, Pablo Bousquets-Muñoz, Romina Royo, Juliette Fontaine, Alexandra Traverse-Glehen, Marco M Bühler, Luca Giudici, Marco Roncador, Thorsten Zenz, Sylvain Carras, Severine Valmary-Degano, Laurence de Leval, Jan Bosch-Schips, Fina Climent, Julia Salmeron-Villalobos, Melika Bashiri, Silvia Ruiz-Gaspà, Dolors Costa, Sílvia Beà, Itziar Salaverria, Eva Giné, Leticia Quintanilla-Martinez, Pierre Brousset, Mark Raffeld, Elaine S Jaffe, Xose S Puente, Cristina López, Ferran Nadeu, Elias Campo
{"title":"Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma.","authors":"Ece Özoğul, Anna Montaner, Melina Pol, Gerard Frigola, Olga Balagué, Charlotte Syrykh, Pablo Bousquets-Muñoz, Romina Royo, Juliette Fontaine, Alexandra Traverse-Glehen, Marco M Bühler, Luca Giudici, Marco Roncador, Thorsten Zenz, Sylvain Carras, Severine Valmary-Degano, Laurence de Leval, Jan Bosch-Schips, Fina Climent, Julia Salmeron-Villalobos, Melika Bashiri, Silvia Ruiz-Gaspà, Dolors Costa, Sílvia Beà, Itziar Salaverria, Eva Giné, Leticia Quintanilla-Martinez, Pierre Brousset, Mark Raffeld, Elaine S Jaffe, Xose S Puente, Cristina López, Ferran Nadeu, Elias Campo","doi":"10.1038/s41408-024-01146-z","DOIUrl":"10.1038/s41408-024-01146-z","url":null,"abstract":"<p><p>Mantle cell lymphoma (MCL) is genetically characterized by the IG::CCND1 translocation mediated by an aberrant V(D)J rearrangement. CCND1 translocations and overexpression have been identified in occasional aggressive B-cell lymphomas with unusual features for MCL. The mechanism generating CCND1 rearrangements in these tumors and their genomic profile are not known. We have reconstructed the IG::CCND1 translocations and the genomic profile of 13 SOX11-negative aggressive B-cell lymphomas using whole genome/exome and target sequencing. The mechanism behind the translocation was an aberrant V(D)J rearrangement in three tumors and by an anomalous IGH class-switch recombination (CSR) or somatic hypermutation (SHM) mechanism in ten. The tumors with a V(D)J-mediated translocation were two blastoid MCL and one high-grade B-cell lymphoma. None of them had a mutational profile suggestive of DLBCL. The ten tumors with CSR/SHM-mediated IGH::CCND1 were mainly large B-cell lymphomas, with mutated genes commonly seen in DLBCL and BCL6 rearrangements in 6. Two cases, which transformed from marginal zone lymphomas, carried mutations in KLF2, TNFAIP3 and KMT2D. These findings expand the spectrum of tumors carrying CCND1 rearrangement that may occur as a secondary event in DLBCL mediated by aberrant CSR/SHM and associated with a mutational profile different from that of MCL.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"14 1","pages":"166"},"PeriodicalIF":12.9,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11420347/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Characterization of MYC Rearrangements in Multiple Myeloma: an Optical Genome Mapping Approach.","authors":"Jung Yoon,Taesung Jeon,Jung-Ah Kwon,Soo-Young Yoon","doi":"10.1038/s41408-024-01147-y","DOIUrl":"https://doi.org/10.1038/s41408-024-01147-y","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"19 1","pages":"165"},"PeriodicalIF":12.8,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142275334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hagop Kantarjian, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Ghayas Issa, Elias Jabbour, Tapan Kadia, Koji Sasaki, Nicholas J. Short, Musa Yilmaz, Farhad Ravandi
{"title":"Current status and research directions in acute myeloid leukemia","authors":"Hagop Kantarjian, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Ghayas Issa, Elias Jabbour, Tapan Kadia, Koji Sasaki, Nicholas J. Short, Musa Yilmaz, Farhad Ravandi","doi":"10.1038/s41408-024-01143-2","DOIUrl":"https://doi.org/10.1038/s41408-024-01143-2","url":null,"abstract":"<p>The understanding of the molecular pathobiology of acute myeloid leukemia (AML) has spurred the identification of therapeutic targets and the development of corresponding novel targeted therapies. Since 2017, twelve agents have been approved for the treatment of AML subsets: the BCL2 inhibitor venetoclax; the CD33 antibody drug conjugate gemtuzumab ozogamicin; three FLT3 inhibitors (midostaurin, gilteritinib, quizartinib); three IDH inhibitors (ivosidenib and olutasidenib targeting <i>IDH1</i> mutations; enasidenib targeting <i>IDH2</i> mutations); two oral hypomethylating agents (oral poorly absorbable azacitidine; fully absorbable decitabine-cedazuridine [latter approved as an alternative to parenteral hypomethylating agents in myelodysplastic syndrome and chronic myelomonocytic leukemia but commonly used in AML]); and CPX-351 (encapsulated liposomal 5:1 molar ratio of cytarabine and daunorubicin), and glasdegib (hedgehog inhibitor). Other targeted therapies (menin inhibitors, CD123 antibody-drug conjugates) are showing promising results. To achieve optimal results in such a rare and heterogeneous entity as AML requires expertise, familiarity with this rare cancer, and the access to, and delivery of disparate therapies under rigorous supportive care conditions. In this review, we update the standard-of-care and investigational therapies and outline promising current and future research directions.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"50 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142245599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Malin Hultcrantz, Hani Hassoun, Neha Korde, Kylee MacLachlan, Sham Mailankody, Dhwani Patel, Urvi A. Shah, Carlyn Rose Tan, David J. Chung, Oscar B. Lahoud, Heather J. Landau, Michael Scordo, Gunjan L. Shah, Sergio A. Giralt, Matthew J. Pianko, Miranda Burge, Kelly Barnett, Meghan Salcedo, Julia Caple, Linh Tran, Jenna Blaslov, Tala Shekarkhand, Selena Hamid, David Nemirovsky, Andriy Derkach, Oluwatobi Arisa, Cody J. Peer, William D. Figg, Saad Z. Usmani, Ola Landgren, Alexander M. Lesokhin
{"title":"Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma","authors":"Malin Hultcrantz, Hani Hassoun, Neha Korde, Kylee MacLachlan, Sham Mailankody, Dhwani Patel, Urvi A. Shah, Carlyn Rose Tan, David J. Chung, Oscar B. Lahoud, Heather J. Landau, Michael Scordo, Gunjan L. Shah, Sergio A. Giralt, Matthew J. Pianko, Miranda Burge, Kelly Barnett, Meghan Salcedo, Julia Caple, Linh Tran, Jenna Blaslov, Tala Shekarkhand, Selena Hamid, David Nemirovsky, Andriy Derkach, Oluwatobi Arisa, Cody J. Peer, William D. Figg, Saad Z. Usmani, Ola Landgren, Alexander M. Lesokhin","doi":"10.1038/s41408-024-01136-1","DOIUrl":"https://doi.org/10.1038/s41408-024-01136-1","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"4 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142245597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sophia Gross, Jana Ihlow, Leonie Busack, Kacper Adamiak, Jens Schrezenmeier, Julia Jesse, Michaela Schwarz, Anne Flörcken, Lam Giang Vuong, Kathrin Rieger, Jan Krönke, Philipp le Coutre, Vivien Boldt, Ann-Christin von Brünneck, David Horst, Thomas Burmeister, Igor-Wolfgang Blau, Ulrich Keller, Lars Bullinger, Jörg Westermann
{"title":"Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy","authors":"Sophia Gross, Jana Ihlow, Leonie Busack, Kacper Adamiak, Jens Schrezenmeier, Julia Jesse, Michaela Schwarz, Anne Flörcken, Lam Giang Vuong, Kathrin Rieger, Jan Krönke, Philipp le Coutre, Vivien Boldt, Ann-Christin von Brünneck, David Horst, Thomas Burmeister, Igor-Wolfgang Blau, Ulrich Keller, Lars Bullinger, Jörg Westermann","doi":"10.1038/s41408-024-01140-5","DOIUrl":"https://doi.org/10.1038/s41408-024-01140-5","url":null,"abstract":"<p>Therapy-related acute myeloid leukemia (t-AML) often exhibits adverse (genetic) features. There is ongoing discussion on the impact of t-AML on long-term outcome in AML. Therefore, we retrospectively analyzed clinical and biological characteristics of 1133 AML patients (225 t-AML patients and 908 de novo AML patients) with a median follow-up of 81.8 months. T-AML patients showed more adverse genetic alterations, higher age and more comorbidities as compared to de novo AML. Median OS in intensively treated t-AML patients was 13.7 months as compared to 39.4 months in de novo AML (<i>p</i> < 0.001). With non-intensive therapy, OS did not differ significantly (<i>p</i> = 0.394). With intensive therapy, significant differences in favor of de novo AML were observed in the ELN intermediate I/II (<i>p</i> = 0.009) and adverse (<i>p</i> = 0.016) risk groups but not within favorable risk groups (APL <i>p</i> = 0.927, ELN favorable <i>p</i> = 0.714). However, t-AML was no independent risk factor for OS (<i>p</i> = 0.103), RR (<i>p</i> = 0.982) and NRM (<i>p</i> = 0.320) in the multivariate analysis. A limitation of our study is an ELN 2010 risk stratification due to a lack of more comprehensive molecular data according to ELN 2022. We conclude that therapeutic algorithms in t-AML, in particular with regard to allo-HSCT, should be guided by ELN genetic risk rather than classification as t-AML alone. Our data support the WHO and ICC 2022 classifications, which include t-AML as diagnostic qualifier rather than a separate subcategory.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"54 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142234435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bon-Kwan Koo, Eun-Ji Choi, Ju Hyun Moon, Ji Yun Kim, Hyunkyung Park, Han-Seung Park, Yunsuk Choi, Jung-Hee Lee, Kyoo-Hyung Lee, Eun Kyung Choi, Eunji Kim, Je-Hwan Lee, Eun-Hye Hur
{"title":"Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia","authors":"Bon-Kwan Koo, Eun-Ji Choi, Ju Hyun Moon, Ji Yun Kim, Hyunkyung Park, Han-Seung Park, Yunsuk Choi, Jung-Hee Lee, Kyoo-Hyung Lee, Eun Kyung Choi, Eunji Kim, Je-Hwan Lee, Eun-Hye Hur","doi":"10.1038/s41408-024-01141-4","DOIUrl":"https://doi.org/10.1038/s41408-024-01141-4","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"46 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142234431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nisha S. Joseph, Jonathan L. Kaufman, Vilas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Lawrence H. Boise, Sara M. DiCamillo, Danielle Roberts, Ajay K. Nooka, Sagar Lonial
{"title":"Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients","authors":"Nisha S. Joseph, Jonathan L. Kaufman, Vilas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Lawrence H. Boise, Sara M. DiCamillo, Danielle Roberts, Ajay K. Nooka, Sagar Lonial","doi":"10.1038/s41408-024-01120-9","DOIUrl":"https://doi.org/10.1038/s41408-024-01120-9","url":null,"abstract":"<p>Lenalidomide, bortezomib, and dexamethasone (RVd) have previously been established as standard-of-care induction therapy for newly diagnosed multiple myeloma (NDMM). More recently, randomized phase 3 data have demonstrated the benefit of the addition of daratumumab (Dara-RVd) to the RVd backbone in terms of improved both depth of response and long-term survival benefit as measured by progression-free survival (PFS). Our group has previously published on a historical cohort of 1000 NDMM patients uniformly treated with RVd induction with impressive both PFS and overall survival. Here, we present a comparative analysis of our RVd cohort with a recent cohort of 326 patients induced with Dara-RVd at our institution with intent to transplant. This analysis demonstrates the utility of this regimen in real-world clinical practice and provides additional insights into D-RVd performance in patient subsets often underrepresented in clinical trials, as well as the impact of daratumumab in maintenance for NDMM patients.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"56 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142174984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carolien C. H. M. Maas, David van Klaveren, Müjde Durmaz, Otto Visser, Djamila E. Issa, Eduardus F. M. Posthuma, Josée M. Zijlstra, Martine E. D. Chamuleau, Pieternella J. Lugtenburg, Marie José Kersten, Avinash G. Dinmohamed
{"title":"Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma","authors":"Carolien C. H. M. Maas, David van Klaveren, Müjde Durmaz, Otto Visser, Djamila E. Issa, Eduardus F. M. Posthuma, Josée M. Zijlstra, Martine E. D. Chamuleau, Pieternella J. Lugtenburg, Marie José Kersten, Avinash G. Dinmohamed","doi":"10.1038/s41408-024-01137-0","DOIUrl":"https://doi.org/10.1038/s41408-024-01137-0","url":null,"abstract":"<p>First-line treatment for advanced-stage diffuse large B-cell lymphoma (DLBCL) typically involves 6x R-CHOP21 or 6x R-CHOP21 with two additional rituximab administrations (6x R-CHOP21 + 2 R). In contemporary practice, this treatment choice might be guided by interim PET scan results. This nationwide, population-based study investigates the comparative effectiveness of these treatment regimens in an era where interim PET-guided treatment decisions were not standard practice. Utilizing the Netherlands Cancer Registry, we identified 1577 adult patients diagnosed with advanced-stage DLBCL between 2014–2018 who completed either 6x R-CHOP21 (43%) or 6x R-CHOP21 + 2 R (57%). We used propensity scores to assess differences in event-free survival (EFS) and overall survival (OS). At five years, EFS (hazard ratio of 6x R-CHOP21 + 2 R versus 6x R-CHOP21 [HR] = 0.89; 95% confidence interval [CI], 0.72–1.09) and OS (HR = 0.93; 95% CI, 0.73–1.18) were not significantly different between both regimens. In exploratory risk-stratified analysis according to the International Prognostic Index (IPI), high-IPI patients (i.e., scores of 4-5) benefit most from 6x R-CHOP21 + 2 R (5-year absolute risk difference of EFS = 16.8%; 95% CI, −0.4%−34.1% and OS = 12.1%; 95% CI, −5.4–29.6%). Collectively, this analysis reveals no significant differences on average in EFS and OS between the two treatments. However, the potential benefits for high-risk patients treated with 6x R-CHOP21 + 2 R underscore the need for future research.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"52 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142170764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
